Bank of America’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-991
| Closed | -$581 | – | 6466 |
|
|
2025
Q4 | $581 | Buy |
991
+12
| +1% | +$14 | ﹤0.01% | 6544 |
|
|
2025
Q3 | $1.85K | Sell |
979
-3
| -0.3% | -$4 | ﹤0.01% | 7412 |
|
|
2025
Q2 | $873 | Buy |
982
+6
| +0.6% | +$4 | ﹤0.01% | 7561 |
|
|
2025
Q1 | $507 | Buy |
976
+1
| +0.1% | +$1 | ﹤0.01% | 7516 |
|
|
2024
Q4 | $497 | Sell |
975
-41
| -4% | -$62 | ﹤0.01% | 7413 |
|
|
2024
Q3 | $3.6K | Buy |
1,016
+42
| +4% | +$267 | ﹤0.01% | 7063 |
|
|
2024
Q2 | $7.7K | Sell |
974
-1,623
| -62% | -$14.7K | ﹤0.01% | 6938 |
|
|
2024
Q1 | $35.2K | Buy |
2,597
+2,592
| +51,840% | +$30.8K | ﹤0.01% | 6612 |
|
|
2023
Q4 | $58 | Buy |
+5
| New | +$56 | ﹤0.01% | 7477 |
|
|
2023
Q2 | – | Hold |
0
| – | -$3 | – | 7850 |
|
|
2023
Q1 | – | Sell |
-19
| Closed | -$480 | – | 7701 |
|
|
2022
Q4 | $466 | Sell |
19
-14
| -42% | -$466 | ﹤0.01% | 7441 |
|
|
2022
Q3 | $1K | Sell |
33
-40
| -55% | -$1.57K | ﹤0.01% | 7680 |
|
|
2022
Q2 | $3K | Hold |
73
| – | – | ﹤0.01% | 7715 |
|
|
2022
Q1 | $3K | Sell |
73
-2,854
| -98% | -$105K | ﹤0.01% | 7984 |
|
|
2021
Q4 | $148K | Buy |
2,927
+2,891
| +8,031% | +$155K | ﹤0.01% | 6669 |
|
|
2021
Q3 | $2K | Buy |
36
+34
| +1,700% | +$1.47K | ﹤0.01% | 7894 |
|
|
2021
Q2 | $0 | Sell |
2
-9
| -82% | -$387 | ﹤0.01% | 7952 |
|
|
2021
Q1 | $1K | Buy |
+11
| New | +$738 | ﹤0.01% | 7324 |
|
|
2020
Q2 | – | Sell |
-824
| Closed | -$25K | – | 7006 |
|
|
2020
Q1 | $25K | Buy |
+824
| New | +$49.8K | ﹤0.01% | 6102 |
|
|
2019
Q2 | – | Sell |
-622
| Closed | -$34K | – | 7328 |
|
|
2019
Q1 | $34K | Buy |
+622
| New | +$33.5K | ﹤0.01% | 6339 |
|
|
2018
Q4 | – | Sell |
-20
| Closed | -$1K | – | 7272 |
|
|
2018
Q3 | $1K | Sell |
20
-984
| -98% | -$21.1K | ﹤0.01% | 7128 |
|
|
2018
Q2 | $22K | Buy |
1,004
+904
| +904% | +$26.1K | ﹤0.01% | 6483 |
|
|
2018
Q1 | $4K | Sell |
100
-53
| -35% | -$2.8K | ﹤0.01% | 6808 |
|
|
2017
Q4 | $9K | Buy |
153
+99
| +183% | +$6.37K | ﹤0.01% | 6633 |
|
|
2017
Q3 | $3K | Buy |
+54
| New | +$3.6K | ﹤0.01% | 6813 |
|
Other funds holding MTNB
VCM
HIW
XT
VFT
Bank of America's MTNB Position: Q1 2026 in Review
Bank of America sold out of Matinas BioPharma (MTNB) in Q1 2026, closing a stake of 991 shares — an estimated $581 sold.
Bank of America first reported a position in MTNB in Q3 2017 and held it in 24 quarters. The position peaked at $148K in Q4 2021. 28 funds tracked by Wall St. Rank hold MTNB as of Q1 2026.
- Bank of America reported no remaining Matinas BioPharma position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 991 Matinas BioPharma shares in Q1 2026, an estimated $581.
- Bank of America first reported a position in Matinas BioPharma in Q3 2017 and held it in 24 quarters.
- Bank of America's Matinas BioPharma position peaked at $148K in Q4 2021.
- 28 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.